Daijiworld Media Network - New Delhi
New Delhi, Aug 8: Multi-omics approaches could strengthen precision medicine for gallbladder cancer by helping identify biomarkers, molecular subtypes and therapeutic targets, according to a narrative review examining recent advances across multiple molecular technologies.
Gallbladder cancer remains the most aggressive malignancy of the biliary tract and is characterised by significant geographic variation, frequent diagnosis at an advanced stage and poor survival outcomes.
The review noted that conventional diagnostic and therapeutic approaches have been limited by the molecular heterogeneity of the disease. Researchers synthesised evidence from genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics to provide a more comprehensive understanding of the biological mechanisms underlying tumour development and progression.
The review highlighted that integrating these complementary datasets has improved understanding of key molecular alterations, dysregulated signalling pathways, metabolic reprogramming and epigenetic modifications associated with disease progression and resistance to treatment.
Together, these findings demonstrate the value of multi-omics analyses in mapping the complex regulatory networks that drive gallbladder cancer.
Across the evidence reviewed, integrated multi-omics approaches identified biomarkers, molecular subtypes and potentially actionable therapeutic targets relevant to precision oncology. The authors said combining molecular information from multiple platforms could support earlier diagnosis, improve patient stratification, guide treatment selection and enhance disease monitoring.
The review also highlighted the emerging role of integrated multi-omics signatures in liquid biopsy platforms, suggesting that these approaches could offer less invasive methods for monitoring the disease and supporting clinical decision-making.
Artificial intelligence-driven integration of complex molecular datasets was also identified as a promising strategy for improving the interpretation of increasingly large and diverse biological datasets.
Despite considerable progress in understanding gallbladder cancer biology, several barriers to clinical implementation remain. These include limited availability of biospecimens, underrepresentation of gallbladder cancer in global datasets and a scarcity of gallbladder cancer-specific clinical trials.
These challenges continue to restrict the validation of potential biomarkers and their translation into routine clinical practice.
The authors concluded that future progress will depend on integrating multi-omics technologies with artificial intelligence, expanding the use of liquid biopsy and developing adaptive clinical trial designs to support personalised therapeutic strategies.
Overall, the review suggests that comprehensive molecular profiling could provide a promising framework for advancing precision medicine and improving diagnosis, treatment selection and clinical outcomes for patients with gallbladder cancer.